Associated Genetic Biomarkers
CDK12 Nonsense is present in 0.25% of AACR GENIE cases, with prostate adenocarcinoma, lung adenocarcinoma, colon adenocarcinoma, high grade ovarian serous adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence .
CDK12 Nonsense serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Nonsense as an inclusion criterion, 1 is phase 2 (1 open).
Trials with CDK12 Nonsense in the inclusion eligibility criteria most commonly target prostate carcinoma .
Durvalumab and olaparib are the most frequent therapies in trials with CDK12 Nonsense as an inclusion criteria .
Significance of CDK12 Nonsense in Diseases
Prostate Carcinoma +
CDK12 is altered in 5.49% of prostate carcinoma patients with CDK12 Nonsense present in 1.43% of all prostate carcinoma patients .
CDK12 Nonsense is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Nonsense and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.